Our Research
This page contains a collection of the most common questions people ask about our practice. If you have a question that isn't answered here, please contact us.

FAQWhat type of patients do you accept?

We do not provide Parkinson’s disease care to the following patients:

  • Institutionalized patients with Parkinson’s disease (nursing homes, etc.)
  • Patients over 75 years old
  • Patients who are taking traditional Parkinson's disease drugs with a total dosing value of L-dopa greater than 1,200 mg per day.

How is this protocol approach different?

Medicine recognizes L-dopa as the most effective Parkinson’s disease treatment available. All other approaches and not as effective. Our method of care is not new; we use the nutritional based active ingredient L-dopa. The difference is standard of care in medicine uses another drug packaged in combination with the L-dopa to manage problems that have plagued treatment with L-dopa for over 50 years (see below). The advantage of our approach is the ability to manage and eliminate these nutritional deficiency based problems and side effects induced by drug co-packaged with L-dopa. This approach is a nutritional deficiency approach, as such the FDA requires us to note that this approach does not cure, treat, mitigate, or prevent disease. Drugs can’t manage nutritional deficiencies.

What problems can depletion of vitamin B6 by traditional Parkinson's disease drugs cause?

  • Induce relative nutritional deficiencies of vitamin B6.
  • Interfere with vitamin B6 dependent processes.
  • Can change dopamine precursors from a nutrient to a drug as side effect develop.
  • Linked to the increasing death rate among Parkinson’s disease patients.
  • Can make symptoms of Parkinson’s disease associated nutritional deficiencies worse.
  • Can accelerate fat soluble neurotoxin-induced brain damage.
  • Can cause dopamine depletion with an associated increase in symptoms.
  • Can cause the nutrients required to make dopamine to quit working.
  • Can induce what were previously thought to be permanent and irreversible dyskinesias and choreiform movement disorder during treatment.


For more information on our approach to Parkinson’s disease send an email to This email address is being protected from spambots. You need JavaScript enabled to view it. or call 218-626-2220. After you send your email, we may ask for more information. All communications will be kept confidential. If you have any questions, please call us free of charge.

The following are the peer-reviewed scientific papers we have published. Do a Google search using the article name to downloads a full-text version of each article.

  1. Trachte, G. Uncini, T. Hinz, M, Both stimulatory and inhibitory effects of dietary 5-hydroxytryptophan and tyrosine are found on urinary excretion of serotonin and dopamine in a large human population Neuropsychiatric Disease and Treatment, 2009, 5:227–2358.

  2. Hinz, M. Depression In: Kohlstadt I. editor. Food and Nutrients in Disease Management CRC Press; 2009, 465-481

  3. Hinz, M. Stein, A, Uncini T. The dual-gate lumen model of renal monoamine transport Neuropsychiatric Disease and Treatment, 2010, 6 387–392
  4. Hinz, M. Stein, A, Trachte, G, Uncini T. Neurotransmitter testing of the urine; a comprehensive analysis. Open Access Journal of Urology 2010:2 177–183

  5. Hinz, M. Stein, A. Uncini T. A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole, NeuroPsychiatric Disease and Treatment Neuropsychiatric Disease and Treatment: 2010, 6:741–747

  6. Stein, A. Hinz, M. Uncini T. Amino acid responsive Crohn’s disease, a case study. Clinical and Experimental Gastroenterology 2010:3 171–177

  7. Hinz, M. Stein A. Uncini T. Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation Neuropsychiatric Disease and Treatment 2011:7 31–38

  8. Hinz, M. Stein, A. Uncini T. Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine Open Access Journal of Urology 2011:3 19–24

  9. Hinz, M. Stein, A. Uncini T. Amino acid management of Parkinson disease: A case study International Journal of General Medicine 2011:4 1–10

  10. Hinz, M. Stein, A. Uncini T. Validity of urinary monoamine assay sales under the “spot baseline urinary neurotransmitter testing marketing model” International Journal of Nephrology and Renovascular Disease 2011:4 101–113

  11. Stein, A. Hinz, M. Uncini T. Microperforation prolotherapy: a novel method for successful nonsurgical treatment of atraumatic spontaneous anterior sternoclavicular subluxation, with an illustrative case Open Access Journal of Sports Medicine 2011:2 47–52

  12. Hinz, M. Stein, A. Uncini T. APRESS: apical regulatory super system, serotonin, and dopamine interaction Neuropsychiatric Disease and Treatment 2011 2011:7 1–7

  13. Hinz, M. Stein, A. Uncini T. Monoamine depletion by reuptake inhibitors International Drug, Healthcare and Patient Safety 2011:3 69–77

  14. Hinz, M. Stein, A. Uncini T. The discrediting of the monoamine hypothesis International Journal of General Medicine 2012:5 135–142

  15. Hinz, M. Stein, A. Uncini T. Relative nutritional deficiencies associated with centrally acting monoamines. International Journal of General Medicine approved March 2012 for publication status in press.

  16. Hinz, M. Stein, A. Uncini T. 5-HTP efficacy and contraindications. International Journal of General Medicine 2012:5 413–430

  17. Hinz, M. et. al. Administration of Supplemental L-tyrosine with Phenelzine: A Clinical Literature Review. Clinical Pharmacology: Advances and Applications 2014:6 107–110 22 July 2014

  18. Hinz, M. et. al. Management of L-dopa overdose in the competitive inhibition state Drug, Healthcare and Patient Safety 2014:6 93–99 22 July 2014

  19. Hinz M. et. al. The Parkinson’s disease death rate Clinical Pharmacology: Advances and Applications 2014:6 161–169 21 October 2014

  20. Hinz, M. et. al. Parkinson’s disease: nausea and dyskinesia Clinical Pharmacology: Advances and Applications 2014:6 189–194 14 November 2014

  21. Hinz, M. et. al. Parkinson’s disease-associated melanin steal Neuropsychiatric Disease and Treatment 2014:10 2331–2337 10 December 2014

  22. Hinz, M. et. al. Parkinson’s disease managing reversible neurodegeneration Neuropsychiatric Disease and Treatment 2016:12 763–775 5 April, 2016

Would you like more information on our unique approach to Parkinson's disease care?